TITLE:
BMS-599626 in Patients With Advanced Solid Malignancies

CONDITION:
Cancer

INTERVENTION:
panHer

SUMMARY:

      The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is
      directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21
      days with a 7 day rest period in patients with cancer who no longer benefit from other
      commonly used treatments. The study will also test for other proteins that may be affected
      by BMS-599626; and the level of study drug in the blood will be studied.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Diagnosis of metastatic cancer that has progressed on currently available therapies;

          -  At least 3 month life expectancy;

          -  Primary cancer must be solid (non-hematologic);

          -  Adequate bone marrow, liver & kidney function;

          -  Negative pregnancy test.

        Exclusion Criteria:

          -  Serious, uncontrolled medical disorder;

          -  Individuals not willing or able to use an acceptable method to avoid pregnancy for
             the entire study period and for at least 3 months after the study;

          -  Pregnant or breastfeeding women;

          -  Patients with known brain metastasis;

          -  Uncontrolled or significant cardiovascular disease;

          -  Anticancer therapy within 2-6 weeks prior to study drug (depending on the therapy)
      
